Not all patients with “type 2” diabetes are equal
Yoel Toledano, Hilla Knobler
Am J Med. 2021;S0002-9343(21)00154-6
Leggi
Breaking news
CGM and glycemic control in young adults with type 1 diabetes: benefit for even the simplest insulin administration methods
Toschi E, Atakov-Castillo A, Clift A, et al.
Diabetes Technol Ther. Pub. online 17 March 2021
Leggi
Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis
Leong A, Cole JB, Brenner LN, et al.
PLoS Med. 2021;18(3):e1003553.
Leggi
A validated prediction model for end-stage kidney disease in type 1 diabetes
Vistisen D, Andersen GS, Hulman A et al.
Diabetes Care. 2021; 44(4):901-907.
Leggi
Social deprivation and incident diabetes-related foot disease in patients with type 2 diabetes: a population-based cohort study
Riley J, Antza C, Kempegowda P, et al.
Diabetes Care. 2021;44(3):731-739
Leggi
Type 2 diabetes subgroups, risk for complications, and differential effects due to an intensive lifestyle intervention
Bancks MP, Chen H, Balasubramanyam A, et al.
Diabetes Care. 2021;dc202372
Leggi
Pre-diabetic patient outcomes 8-15 years after drug-eluting coronary stenting
Ellis SG, Cho L, Raymond R, et al.
The American Journalk of Cardiology. Pub. online 19 March 2021
Leggi
Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in Asian versus white patients with and without type 2 diabetes
Lee MMY, Ghouri N, McGuire DK, et al.
Diabetes Care. 2021;dc203007
Leggi
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction
Adler AI, Douch E, Dunning L, et al.
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00072-3
Leggi
Cardiovascular consequences of gestational diabetes
Green JB
Circulation. 2021;143(10):988-990
Leggi